ESCALADE INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ESCALADE INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 28, 2019 | $180.54M | Feb 21, 2020 |
| FY2018 | Dec 29, 2018 | $50.99M | Feb 22, 2019 |
| FY2018 | Oct 6, 2018 | $43.96M | Feb 22, 2019 |
| FY2018 | Jul 14, 2018 | $48.68M | Feb 22, 2019 |
| FY2018 | Mar 24, 2018 | $32.15M | Feb 22, 2019 |
| FY2018 | Dec 30, 2017 | $48.69M | Feb 22, 2019 |
| FY2018 | Oct 7, 2017 | $42.86M | Feb 22, 2019 |
| FY2018 | Jul 15, 2017 | $53.92M | Feb 22, 2019 |
| FY2018 | Mar 25, 2017 | $31.87M | Feb 22, 2019 |
| FY2018 | Dec 31, 2016 | $171.66M | Feb 22, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $240.16M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $251.51M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $263.57M | Mar 10, 2025 |
| FY2022 | Dec 31, 2022 | $72.14M | Mar 29, 2024 |
| FY2022 | Oct 1, 2022 | $74.90M | Mar 29, 2024 |
| FY2022 | Jul 9, 2022 | $94.34M | Mar 29, 2024 |
| FY2022 | Mar 19, 2022 | $72.38M | Mar 29, 2024 |
| FY2022 | Dec 25, 2021 | $73.44M | Mar 29, 2024 |
| FY2022 | Oct 2, 2021 | $81.30M | Mar 29, 2024 |
| FY2022 | Jul 10, 2021 | $99.68M | Mar 29, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | May 17, 2018 | $6.02M | Feb 22, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.70M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $12.99M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $9.83M | Mar 10, 2025 |
| FY2022 | Dec 31, 2022 | $2.70M | Mar 29, 2024 |
| FY2022 | Oct 1, 2022 | $2.96M | Mar 29, 2024 |
| FY2022 | Jul 9, 2022 | $5.67M | Mar 29, 2024 |
| FY2022 | Mar 19, 2022 | $6.65M | Mar 29, 2024 |
| FY2022 | Dec 25, 2021 | $4.87M | Mar 29, 2024 |
| FY2022 | Oct 2, 2021 | $5.97M | Mar 29, 2024 |
| FY2022 | Jul 10, 2021 | $8.13M | Mar 29, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.73M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $20.00M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $17.81M | Mar 10, 2025 |
| FY2022 | Dec 31, 2022 | $4.88M | Mar 29, 2024 |
| FY2022 | Oct 1, 2022 | $4.22M | Mar 29, 2024 |
| FY2022 | Jul 9, 2022 | $8.19M | Mar 29, 2024 |
| FY2022 | Mar 19, 2022 | $9.02M | Mar 29, 2024 |
| FY2022 | Dec 25, 2021 | $6.41M | Mar 29, 2024 |
| FY2022 | Oct 2, 2021 | $7.67M | Mar 29, 2024 |
| FY2022 | Jul 10, 2021 | $10.69M | Mar 29, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.20M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.20M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $3.10M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $2.70M | Mar 29, 2024 |
| FY2023 | Dec 25, 2021 | $2.00M | Mar 29, 2024 |
| FY2022 | Dec 26, 2020 | $1.50M | Mar 29, 2024 |
| FY2021 | Dec 28, 2019 | $1.60M | Feb 22, 2022 |
| FY2020 | Dec 29, 2018 | $1.50M | Feb 22, 2021 |
| FY2019 | Dec 30, 2017 | $1.60M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $1.50M | Feb 22, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.63M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $43.30M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $41.48M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $44.77M | Mar 29, 2024 |
| FY2023 | Dec 25, 2021 | $43.37M | Mar 29, 2024 |
| FY2022 | Dec 26, 2020 | $40.32M | Mar 29, 2024 |
| FY2021 | Dec 28, 2019 | $31.62M | Feb 22, 2022 |
| FY2020 | Dec 29, 2018 | $29.81M | Feb 22, 2021 |
| FY2019 | Dec 30, 2017 | $28.55M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $27.36M | Feb 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $31.01M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $36.05M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $48.33M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $8.58M | Mar 29, 2024 |
| FY2023 | Dec 25, 2021 | $1.07M | Mar 29, 2024 |
| FY2022 | Dec 26, 2020 | $2.63M | Mar 29, 2024 |
| FY2021 | Dec 28, 2019 | $16.04M | Feb 22, 2022 |
| FY2020 | Dec 29, 2018 | $6.51M | Feb 22, 2021 |
| FY2019 | Dec 30, 2017 | $13.36M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $12.17M | Feb 22, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.51M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.04M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.09M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $2.11M | Mar 29, 2024 |
| FY2023 | Dec 25, 2021 | $9.70M | Mar 29, 2024 |
| FY2022 | Dec 26, 2020 | $5.46M | Mar 29, 2024 |
| FY2021 | Dec 28, 2019 | $2.19M | Feb 22, 2022 |
| FY2020 | Dec 29, 2018 | $2.82M | Feb 22, 2021 |
| FY2019 | Dec 30, 2017 | $2.75M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $2.65M | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $222.11M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $226.33M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $253.01M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $298.72M | Mar 29, 2024 |
| FY2023 | Dec 25, 2021 | $251.80M | Mar 29, 2024 |
| FY2022 | Dec 26, 2020 | $220.71M | Mar 29, 2024 |
| FY2021 | Dec 28, 2019 | $148.78M | Feb 22, 2022 |
| FY2020 | Dec 29, 2018 | $149.53M | Feb 22, 2021 |
| FY2019 | Dec 30, 2017 | $156.11M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $150.76M | Feb 22, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.89M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $57.33M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $88.43M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $140.24M | Mar 29, 2024 |
| FY2022 | Dec 25, 2021 | $105.18M | Mar 29, 2024 |
| FY2021 | Dec 26, 2020 | $81.55M | Feb 22, 2022 |
| FY2020 | Dec 28, 2019 | $22.61M | Feb 22, 2021 |
| FY2019 | Dec 29, 2018 | $21.21M | Feb 21, 2020 |
| FY2018 | Dec 30, 2017 | $44.44M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $49.05M | Feb 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $173.22M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $169.00M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $164.58M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $158.48M | Mar 10, 2025 |
| FY2023 | Dec 25, 2021 | $146.62M | Mar 29, 2024 |
| FY2023 | Dec 26, 2020 | $139.16M | Mar 29, 2024 |
| FY2022 | Dec 28, 2019 | $126.17M | Mar 29, 2024 |
| FY2021 | Dec 29, 2018 | $128.32M | Feb 22, 2022 |
| FY2020 | Dec 30, 2017 | $111.67M | Feb 22, 2021 |
| FY2019 | Dec 31, 2016 | $101.71M | Feb 21, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $42.33M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $42.33M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $42.33M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $42.33M | Mar 29, 2024 |
| FY2023 | Dec 25, 2021 | $32.70M | Mar 29, 2024 |
| FY2022 | Dec 26, 2020 | $32.70M | Mar 29, 2024 |
| FY2021 | Dec 28, 2019 | $26.75M | Feb 22, 2022 |
| FY2020 | Dec 29, 2018 | $26.38M | Feb 22, 2021 |
| FY2018 | Dec 30, 2017 | $21.55M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $21.46M | Feb 27, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $170.20M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $164.78M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $160.10M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $156.45M | Mar 29, 2024 |
| FY2023 | Dec 25, 2021 | $146.62M | Mar 29, 2024 |
| FY2021 | Dec 26, 2020 | $125.24M | Feb 22, 2022 |
| FY2020 | Dec 28, 2019 | $111.96M | Feb 22, 2021 |
| FY2019 | Dec 29, 2018 | $113.88M | Feb 21, 2020 |
| FY2018 | Dec 30, 2017 | $99.91M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $91.69M | Feb 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 29, 2018 | $2.82M | Feb 22, 2019 |
| FY2018 | Dec 30, 2017 | $1.57M | Feb 22, 2019 |
| FY2018 | Dec 31, 2016 | $1.01M | Feb 22, 2019 |
| FY2018 | Dec 26, 2015 | $1.98M | Feb 22, 2019 |
| FY2015 | Dec 27, 2014 | $3.23M | Feb 23, 2016 |
| FY2014 | Dec 28, 2013 | $1.09M | Feb 25, 2015 |
| FY2013 | Dec 29, 2012 | $2.54M | Feb 25, 2014 |
| FY2013 | Dec 31, 2011 | $3.82M | Feb 25, 2014 |
| FY2013 | Dec 25, 2010 | $1.54M | Feb 25, 2014 |
| FY2012 | Dec 26, 2009 | $3.04M | Feb 26, 2013 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.45M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $25.60M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $50.90M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $94.88M | Mar 29, 2024 |
| FY2022 | Dec 25, 2021 | $57.54M | Mar 29, 2024 |
| FY2021 | Dec 26, 2020 | $30.07M | Feb 22, 2022 |
| FY2018 | Dec 29, 2018 | $0 | Feb 22, 2019 |
| FY2018 | Dec 30, 2017 | $23.12M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $25.44M | Feb 27, 2018 |
| FY2016 | Dec 26, 2015 | $23.14M | Feb 28, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 10, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Oct 1, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Jul 9, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Mar 19, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 25, 2021 | 0 | Mar 29, 2024 |
| FY2022 | Oct 2, 2021 | 0 | Mar 29, 2024 |
| FY2022 | Jul 10, 2021 | 0 | Mar 29, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 10, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Oct 1, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Jul 9, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Mar 19, 2022 | 0 | Mar 29, 2024 |
| FY2022 | Dec 25, 2021 | 0 | Mar 29, 2024 |
| FY2022 | Oct 2, 2021 | 0 | Mar 29, 2024 |
| FY2022 | Jul 10, 2021 | 0 | Mar 29, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 13.70M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 13.73M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 13.74M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 13.59M | Mar 29, 2024 |
| FY2022 | Dec 25, 2021 | 13.49M | Mar 29, 2024 |
| FY2021 | Dec 26, 2020 | 13.92M | Feb 22, 2022 |
| FY2020 | Dec 28, 2019 | 14.21M | Feb 22, 2021 |
| FY2019 | Dec 29, 2018 | 14.44M | Feb 21, 2020 |
| FY2018 | Dec 30, 2017 | 14.37M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | 14.30M | Feb 27, 2018 |